Articles by Prabarna Ganguly, Ph.D.

February 17, 2021 — The NHGRI Short Course in Genomics brings the latest genomics science to the classroom.

January 19, 2021 — NHGRI has appointed Neil Hanchard, M.D., Ph.D., as a clinical investigator within the Medical Genomics and Metabolic Genetics Branch (MGMGB) in the Division of Intramural Research. Dr. Hanchard will head the Childhood Complex Disease Genomics Section within the MGMGB.

January 07, 2021 — NHGRI has released a new action agenda for a diverse genomics workforce. This ambitious set of goals, objectives, and implementation strategies details NHGRI’s plans for enhancing the diversity of the genomics workforce by 2030.

January 06, 2021 — Using a recently developed DNA base-editing technique, researchers correct accelerating aging disorder.

January 04, 2021 — Researchers from NHGRI, Oxford University and other National Institutes of Health centers have developed and tested a new method to predict hospital-acquired infections involving five other important pathogens.

December 17, 2020 — A 2018 workshop led by Alaska Native people provides a path towards collaborative, community-driven genomics research.

December 08, 2020 — Dr. Wilson officially retired from The National Human Genome Research Institute (NHGRI) in September 2020, yet he remains on as a scientist emeritus in its Computational and Statistical Genomics Branch, where he was co-chief for 14 years.

October 28, 2020 — NHGRI published its “Strategic vision for improving human health at The Forefront of Genomics” in the journal Nature. This vision describes the most compelling research priorities and opportunities in human genomics for the coming decade, signaling a new era in genomics for the Institute and the field.

October 27, 2020 — NHGRI researchers have discovered a new inflammatory disorder called vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic syndrome (VEXAS), which is caused by mutations in the UBA1 gene.

October 12, 2020 — NHGRI researchers asked patients, parents and physicians in the sickle cell disease community (SCD) what they wanted and needed to know about genome editing to make informed decisions about participating in genome-editing clinical trials.